Experimental: Human Urinary Kallidinogenase
PreclinicalProtein / enzyme
Experimental: Human Urinary Kallidinogenase is one of 38 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Reminyl
WWim Janssens
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company
- HHuashan Hospital